SCD and Alzheimer disease: A higher mean SCD‐severity would thus reflect these later stages and, in combination with abnormal AD biomarkers, represent a clinical stage 2b of biological AD (quite rare in our sample, about 6% [4%–8%] of participants are SCD+Aβ+T+).